4-Methyl-2-oxovaleric acid

CAS No. 816-66-0

4-Methyl-2-oxovaleric acid( 4-Methyl-2-oxopentanoic acid )

Catalog No. M19851 CAS No. 816-66-0

4-Methyl-2-oxopentanoic acid is an abnormal metabolite that arises from the incomplete breakdown of branched-chain amino acids. It is both a neurotoxin and a metabotoxin.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 54 In Stock
25MG 29 In Stock
50MG 36 In Stock
100MG 49 In Stock
200MG Get Quote In Stock
500MG 110 In Stock
1G 163 In Stock

Biological Information

  • Product Name
    4-Methyl-2-oxovaleric acid
  • Note
    Research use only, not for human use.
  • Brief Description
    4-Methyl-2-oxopentanoic acid is an abnormal metabolite that arises from the incomplete breakdown of branched-chain amino acids. It is both a neurotoxin and a metabotoxin.
  • Description
    4-Methyl-2-oxopentanoic acid is an abnormal metabolite that arises from the incomplete breakdown of branched-chain amino acids. It is both a neurotoxin and a metabotoxin.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    4-Methyl-2-oxopentanoic acid
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    816-66-0
  • Formula Weight
    130.14
  • Molecular Formula
    C6H10O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CC(C)CC(=O)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yudkoff M et al. Brain amino acid requirements and toxicity: the example of leucine. J Nutr. 2005 Jun;135(6 Suppl):1531S-8S.
molnova catalog
related products
  • Head activator

    Head activator neuropeptide is a mitogen for mammalian cell lines of neuronal or neuroendocrine origin. Head activator neuropeptide signals by binding GPR37 and stimulates cells to enter mitosis.

  • LY-3475070

    LY-3475070 is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.

  • Présure. 10. 145-148

    Présure. 10. 145-148